logo-loader
viewAdial Pharmaceuticals Inc

Adial Pharmaceuticals making progress with alcohol use disorder drug

Adial Pharmaceuticals Inc (NASDAQ:ADIL) CEO William Stilley spoke with Proactive Investors at the MicroCap Conference in New York.

Adial Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of a therapeutic agent for the treatment of alcohol use disorder using its lead investigational new drug product, AD04, a selective serotonin-3 antagonist.

Quick facts: Adial Pharmaceuticals Inc

Price: 1.37 USD

NASDAQ:ADIL
Market: NASDAQ
Market Cap: $14.14 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fidelity Minerals sees exciting road ahead for company with...

Fidelity Minerals (CVE: FMN) CEO Ian Graham joined Steve Darling from Proactive Vancouver on Skype to provide a corporate update. Graham discussed the latest on the recent sale of their Cerro Dorado asset and why they decided to do a share consolidation. Graham also discusses the shift in...

8 hours, 3 minutes ago

2 min read